The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Recent Advances in the Treatment of Breast Cancer
Open accessAbstract
Breast cancer (BC) is the most common malignancy in women. It is classified into a few major molecular subtypes according to hormone and growth factor receptor expression. Over the past few years, substantial advances have been made in the discovery of new drugs for treating BC. Improved understanding of the biologic heterogeneity of BC has allowed the development of more effective and individualized approach to treatment. In this review, we provide an update about the current treatment strategy and discuss the various emerging novel therapies for the major molecular subtypes of BC. A brief account of the clinical development of inhibitors of poly(ADP-ribose) polymerase, cyclin-dependent kinases 4 and 6, phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathway, histone deacetylation, multi-targeting tyrosine kinases, and immune checkpoints for personalized treatment of BC is included. However, no targeted drug has been approved for the most aggressive subtype-triple negative breast cancer (TNBC). Thus, we discuss the heterogeneity of TNBC and how molecular subtyping of TNBC may help drug discovery for this deadly disease. The emergence of drug resistance also poses threat to the successful development of targeted therapy in various molecular subtypes of BC. New clinical trials should incorporate advanced methods to identify changes induced by drug treatment, which may be associated with the upregulation of compensatory signaling pathways in drug resistant cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,030
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Prat, A., Parker, J. S., Karginova, O., Fan, C., Livasy, C., Herschkowitz, J. I., He, X., & Perou, C. M. (2010) · Breast Cancer Research · doi:10.1186/bcr2635 · Cited by 2,167
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039 · cited 1×
“They were shown to significantly improve median PFS by 10 months (16) and PFS rate by 20% after 18 months (17), respectively, compared to letrozole alone.”
BackgroundCristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680 · cited 1×
“As second-line treatment in combination with fulvestrant in HR+/HER2− advanced BC, palbociclib and abemaciclib were demonstrated to significantly prolong median PFS by 5 months (18) and 7 months (19), respectively, compared to fulvestrant alone.”
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
Tamoxifen in the Treatment of Breast Cancer
Osborne, C. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392207 · Cited by 1,320
Robert, N. J., Diéras, V., Glaspy, J., Brufsky, A. M., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y. T., Zhou, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0982 · Cited by 1,064
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/134.7.e48 · Cited by 1,042
Heterogeneity in breast cancer
Polyak, K. (2011) · Journal of Clinical Investigation · doi:10.1172/jci60534 · Cited by 1,006
Miles, D. W., Chan, A., Dirix, L. Y., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J. H., Provencher, L., Puglisi, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6457 · Cited by 897
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/134.6.907 · Cited by 895
Gianni, L., Dafni, U., Gelber, R. D., Azambuja, E., Muehlbauer, S., Goldhirsch, A., Untch, M., Smith, I., Baselga, J., Jackisch, C., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70033-x · Cited by 612
Chan, A., Delaloge, S., Holmes, F. A., Moy, B., Iwata, H., Harvey, V. J., Robert, N. J., Silovski, T., Gokmen, E., von Minckwitz, G., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00551-3 · Cited by 561
Miller, T. W., Hennessy, B. T., González-Angulo, A. M., Fox, E. M., Mills, G. B., Chen, H., Higham, C., García-Echeverría, C., Shyr, Y., & Arteaga, C. L. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41680 · Cited by 551
Fisk, B., Blevins, T. L., Wharton, J. T., & Ioannides, C. G. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.6.2109 · Cited by 543
Carey, L. A., Rugo, H. S., Marcom, P. K., Mayer, E. L., Esteva, F. J., Ma, C. X., Liu, M. C., Storniolo, A. M., Rimawi, M. F., Forero-Torres, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5579 · Cited by 499
Miller, T. W., Rexer, B. N., Garrett, J. T., & Arteaga, C. L. (2011) · Breast Cancer Research · doi:10.1186/bcr3039 · Cited by 462
HER2 therapy: Molecular mechanisms of trastuzumab resistance
Nahta, R., & Esteva, F. J. (2006) · Breast Cancer Research · doi:10.1186/bcr1612 · Cited by 433
Yang, X., Phillips, D. L., Ferguson, A. T., Nelson, W. G., Herman, J. G., & Davidson, N. E. (2001) · PubMed · Cited by 430
Yardley, D. A., Ismail-Khan, R. R., Melichar, B., Lichinitser, M., Munster, P. N., Klein, P. M., Cruickshank, S., Miller, K. D., Lee, M. J., & Trepel, J. B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7251 · Cited by 423
Timms, K. M., Abkevich, V., Hughes, E., Neff, C., Reid, J., Morris, B., Kalva, S., Potter, J., Tran, T. V., Chen, J., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0475-x · Cited by 419
Munster, P. N., Thurn, K. T., Thomas, S., Raha, P., Lacevic, M., Miller, A., Melisko, M., Ismail-Khan, R., Rugo, H., Moasser, M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.156 · Cited by 391
Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer
Mehta, R. S., Barlow, W. E., Albain, K. S., Vandenberg, T. A., Dakhil, S. R., Tirumali, N. R., Lew, D. L., Hayes, D. F., Gralow, J. R., Livingston, R. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201622 · Cited by 371
Baselga, J., Gómez, P., Greil, R., Braga, S., Climent, M. A., Wardley, A. M., Kaufman, B., Stemmer, S. M., Pêgo, A., Chan, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2408 · Cited by 363
Linderholm, B. K., Hellborg, H., Johansson, U., Elmberger, G., Skoog, L., Lehtiö, J., & Lewensohn, R. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp062 · Cited by 347
Hurvitz, S. A., Andre, F., Jiang, Z., Shao, Z., Mano, M. S., Neciosup, S. P., Tseng, L.-M., Zhang, Q., Shen, K., Liu, D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00051-0 · Cited by 306
Krop, I. E., Mayer, I. A., Ganju, V., Dickler, M., Johnston, S., Morales, S., Yardley, D. A., Melichar, B., Forero-Torres, A., Lee, S. C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00106-6 · Cited by 295
Incidence of Breast Cancer in the United States: Current and Future Trends
Anderson, W. F., Katki, H. A., & Rosenberg, P. S. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr257 · Cited by 285
Past, Present, and Future Challenges in Breast Cancer Treatment
Sledge, G. W., Mamounas, E. P., Hortobagyi, G. N., Burstein, H. J., Goodwin, P. J., & Wolff, A. C. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.4139 · Cited by 277
Johnston, S. R., Kilburn, L. S., Ellis, P., Dodwell, D., Cameron, D., Hayward, L., Im, Y.-H., Braybrooke, J. P., Brunt, A. M., Cheung, K.-L., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70322-x · Cited by 274
Wolff, A. C., Lazar, A. A., Bondarenko, I., Garin, A. M., Brincat, S., Chow, L., Sun, Y., Neskovic-Konstantinovic, Z., Guimaraes, R. C., Fumoleau, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.3331 · Cited by 272
Bergh, J., Jönsson, P.-E., Lidbrink, E. K., Trudeau, M., Eiermann, W., Brattström, D., Lindemann, J. P. O., Wiklund, F., & Henriksson, R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.1095 · Cited by 263
Impact of Breast Cancer Subtypes and Treatment on Survival: An Analysis Spanning Two Decades
Haque, R., Ahmed, S. A., Inzhakova, G., Shi, J., Avila, C., Polikoff, J., Bernstein, L., Enger, S. M., & Press, M. F. (2012) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-12-0474 · Cited by 249
Mittendorf, E. A., Clifton, G. T., Holmes, J. P., Schneble, E., van Echo, D., Ponniah, S., & Peoples, G. E. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu211 · Cited by 248
Bang, Y. J., Giaccone, G., Im, S. A., Oh, D. Y., Bauer, T. M., Nordstrom, J. L., Li, H., Chichili, G. R., Moore, P. A., Hong, S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx002 · Cited by 226
Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study
Finn, R. S., Bengala, C., Ibrahim, N., Roché, H., Sparano, J., Strauss, L. C., Fairchild, J., Sy, O., & Goldstein, L. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0288 · Cited by 220
Konecny, G. E., & Kristeleit, R. S. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.311 · Cited by 216
Rose, A. A. N., Grosset, A.-A., Dong, Z., Russo, C., MacDonald, P. A., Bertos, N. R., St-Pierre, Y., Simantov, R., Hallett, M., Park, M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1611 · Cited by 194
Han, H. S., Diéras, V., Robson, M., Palácová, M., Marcom, P. K., Jager, A., Bondarenko, I., Citrin, D., Campone, M., Telli, M. L., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx505 · Cited by 194
Yardley, D. A., Weaver, R., Melisko, M. E., Saleh, M. N., Arena, F. P., Forero, A., Cigler, T., Stopeck, A., Citrin, D., Oliff, I., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2959 · Cited by 190
Recent advances of highly selective CDK4/6 inhibitors in breast cancer
Xu, H., Yu, S., Liu, Q., Yuan, X., Mani, S., Pestell, R. G., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0467-2 · Cited by 168
Sabnis, G. J., Goloubeva, O., Chumsri, S., Nguyen, N., Sukumar, S., & Brodie, A. M. H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2458 · Cited by 158
Optimal management of hormone receptor positive metastatic breast cancer in 2016
Reinert, T., & Barrios, C. H. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015608993 · Cited by 158
Genomic Architecture Characterizes Tumor Progression Paths and Fate in Breast Cancer Patients
Russnes, H. G., Vollan, H. K. M., Lingjærde, O. C., Krasnitz, A., Lundin, P., Naume, B., Sørlie, T., Borgen, E., Rye, I. H., Langerød, A., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000611 · Cited by 152
PARP inhibitors: the race is on
Brown, J. S., Kaye, S. B., & Yap, T. A. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.67 · Cited by 149
Saura, C., Bendell, J. C., Jérusalem, G., Su, S., Ru, Q. C., Buck, S., Mills, D., Ruquet, S., Bosch, A., Urruticoechea, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1070 · Cited by 143
Triple-negative breast cancer: new perspectives for targeted therapies
Tomao, F., Tomao, F., Rossi, L., Zaccarelli, E., Caruso, D., Minozzi, M., Frati, L., Papa, A., & Vici (2015) · OncoTargets and Therapy · doi:10.2147/ott.s67673 · Cited by 140
Telli, M. L., Hellyer, J. A., Audeh, W., Jensen, K. C., Bose, S., Timms, K. M., Gutin, A., Abkevich, V., Peterson, R. N., Neff, C. D., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4624-7 · Cited by 138
Adams, S., Schmid, P., Rugo, H. S., Winer, E. P., Loirat, D., Awada, A. H., Cescon, D. W., Iwata, H., Campone, M., Nanda, R., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.1008 · Cited by 132
Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
Barroso‐Sousa, R., Shapiro, G. I., & Tolaney, S. M. (2016) · Breast Care · doi:10.1159/000447284 · Cited by 114
Steroid Sulfatase: A New Target for the Endocrine Therapy of Breast Cancer
Stanway, S. J., Delavault, P., Purohit, A., Woo, L. W. L., Thurieau, C., Potter, B. V. L., & Reed, M. J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-4-370 · Cited by 108
Hudis, C. A., Swanton, C., Janjigian, Y. Y., Lee, R., Sutherland, S., Lehman, R. J., Chandarlapaty, S., Hamilton, N., Gajria, D., Knowles, J., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3577 · Cited by 107
Rose, A. A. N., Biondini, M., Curiel, R. E., & Siegel, P. M. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.05.010 · Cited by 105
Schmid, P., Pinder, S. E., Wheatley, D. A., Macaskill, J., Zammit, C., Hu, J. J., Price, R., Bundred, N. J., Hadad, S. M., Shia, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9179 · Cited by 97
Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
Hamilton, E. P., Blackwell, K., Hobeika, A. C., Clay, T. M., Broadwater, G., Ren, X.-R., Chen, W. R., Castro, H. J., Lehmann, F. F., Spector, N. L., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-28 · Cited by 96
Dickler, M. N., Saura, C., Richards, D., Krop, I. E., Cervantes, A. M. R., Bedard, P. L., Patel, M. R., Pusztai, L., Oliveira, M., Cardenas, A. K., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0613 · Cited by 83
Phase II trial of temsirolimus in patients with metastatic breast cancer
Fleming, G. F., Ma, C. X., Huo, D., Sattar, H. A., Tretiakova, M., Li, L., Hahn, O. M., Olopade, F. O., Nanda, R., Hoffman, P. C., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1910-7 · Cited by 82
The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer
Shah, A. N., & Cristofanilli, M. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0443-7 · Cited by 71
Steroid sulfatase: A pivotal player in estrogen synthesis and metabolism
Purohit, A., Woo, L. W. L., & Potter, B. V. L. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.06.012 · Cited by 68
Guérin, M., Rezaï, K., Isambert, N., Campone, M., Autret, A., Pakradouni, J., Provansal, M., Camerlo, J., Sabatier, R., Bertucci, F., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.08.025 · Cited by 62
Tolaney, S. M., Burris, H. A., Gartner, E. M., Mayer, I. A., Saura, C., Maurer, M., Ciruelos, E., García, A. A., Campana, F., Wu, B., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3248-4 · Cited by 59
participants, O. B. O. T. I. T., Palmieri, C., Stein, R. C., Liu, X., Hudson, E., Nicholas, H., Sasano, H., Guestini, F., Holcombe, C., Barrett, S., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4328-z · Cited by 59
Leo, A. D., Lee, K. S., Ciruelos, E. M., Lønning, P. E., Janni, W., O'Regan, R. M., Mouret-Reynier, M.-A., Kalev, D. N., Egle, D., Csőszi, T., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.sabcs16-s4-07 · Cited by 55
Turner, N. C., Telli, M. L., Rugo, H. S., Mailliez, A., Ettl, J., Grischke, E., Mina, L. A., Balmañà, J., Fasching, P. A., Hurvitz, S. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.1007 · Cited by 54
Smith, C. A., Pollice, A. A., Gu, L. P., Brown, K. A., Singh, S., Janocko, L. E., Johnson, R. C., Julian, T. B., Hyams, D. M., Wolmark, N., et al. (2000) · PubMed · Cited by 47
Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells
Kim, E. M. H., Mueller, K., Gartner, E. M., & Boerner, J. L. (2013) · Journal of Surgical Research · doi:10.1016/j.jss.2013.06.041 · Cited by 47
Curigliano, G., Romieu, G., Campone, M., Dorval, T., Duck, L., Canon, J.-L. R., Roemer-Bécuwe, C., Roselli, M., Neciosup, S. P., Burny, W., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3750-y · Cited by 45
Rasmussen, L. M., Zaveri, N. T., Stenvang, J., Peters, R. H., & Lykkesfeldt, A. E. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9494-y · Cited by 44
Perez, E. A. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.001 · Cited by 43
Blackwell, K., Burris, H. A., Gómez, P., Henry, N. L., Isakoff, S. J., Campana, F., Gao, L., Jiang, J., Macé, S., & Tolaney, S. M. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3615-9 · Cited by 37
Mukai, H., Saeki, T., Aogi, K., Naito, Y., Matsubara, N., Shigekawa, T., Ueda, S., Takashima, S., Hara, F., Yamashita, T., et al. (2016) · Cancer Science · doi:10.1111/cas.13017 · Cited by 37
The role of carboplatin in the neoadjuvant chemotherapy treatment of triple negative breast cancer
Castrellon, A. B., Pidhorecky, I., Valero, V., & Raez, L. E. (2017) · Oncology Reviews · doi:10.4081/oncol.2017.324 · Cited by 37
Seiler, M., Ray-Coquard, I. L., Melichar, B., Yardley, D. A., Wang, R. X., Dodion, P. F., & Lee, M. A. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.07.008 · Cited by 33
The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer
Dieras, V. C., & Bachelot, T. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0287-4 · Cited by 32
Chien, A. J., Cockerill, A., Fancourt, C., Schmidt, E. V., Moasser, M. M., Rugo, H. S., Melisko, M., Ko, A. H., Kelley, R. K., Korn, W. M., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3701-7 · Cited by 32
Limentani, S. A., Campone, M., Dorval, T., Curigliano, G., BOER, R. D., Vogel, C. L., White, S. C., Bachelot, T., Canon, J.-L. R., Disis, M. L., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3751-x · Cited by 31
Potential of antibody–drug conjugates and novel therapeutics in breast cancer management
Roukos, D. H., Lianos, G. D., Bali, C. D., Vlachos, K., Zoras, O., Katsios, C. G., Tzaphlidou, M., & Cho, Y. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s34235 · Cited by 29
Acevedo-Gadea, C. R., Hatzis, C., Chung, G. G., Fischbach, N. A., Lezon-Geyda, K., Zelterman, D. A., DiGiovanna, M. P., Harris, L. N., & Abu-Khalaf, M. M. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3292-8 · Cited by 29
Kerklaan, B. M., Dieras, V. C., Tourneau, C. L., Mergui‐Roelvink, M., Huitema, A. D. R., Rosing, H., Beijnen, J. H., Marreaud, S. I., Govaerts, A.-S., Piccart, M. J., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1972-1 · Cited by 23
Saura, C., de Azambuja, E., Hlauschek, D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx440.001 · Cited by 23
Cited by
Breast Cancer Statistics, 2022
Giaquinto, A. N., Sung, H., Miller, K. D., Kramer, J. L., Newman, L. A., Minihan, A., Jemal, A., & Siegel, R. L. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21754 · Cited by 2,286
Paclitaxel’s Mechanistic and Clinical Effects on Breast Cancer
Abu Samaan, T. M., Samec, M., Liskova, A., Kubatka, P., & Büsselberg, D. (2019) · Biomolecules · doi:10.3390/biom9120789 · Cited by 569
An overview of PROTACs: a promising drug discovery paradigm
Liu, Z., Hu, M., Yang, Y., Du, C., Zhou, H., Liu, C., Chen, Y., Fan, L., Ma, H., Gong, Y., et al. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00112-0 · Cited by 344
Current State of Breast Cancer Diagnosis, Treatment, and Theranostics
Bhushan, A., Gonsalves, A., & Menon, J. U. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050723 · Cited by 298
Hu, J., Hu, B., Wang, M., Xu, F., Miao, B., Yang, C.-Y., Wang, M., Liu, Z., Hayes, D. F., Chinnaswamy, K., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01572 · Cited by 268
Metadata
- Authors
- Tong, C. W. S., Wu, M., Cho, W. C. S., & To, K. K. W.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2018-06-14
- Volume
- 8
- Pages
- 227-227
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2807500538
- Cited by
- 399
- References
- 92
- FWCI
- 11.45
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.